Revenue $102.821M
EBITDA -$67.61
Income -$103.43
Revenue Q/Q -65.38%
Revenue Y/Y -13.96%
P/E 0.00
Forward P/E N/A
EV/Sales 0.08
EV/EBITDA N/A
EV/EBIT N/A
PEG 0.19
Price/Sales 0.67
P/FCF N/A
Price/Book -10.62
Book/Share 0.00
Cash/Share 3.64
FCF yield -109.14%
Employees 0
RPE N/A
Volume 1.755M / 12.583k
Relative vol. 139.47 ×
EPS N/A
EPS Q/Q -15.15%
Est. EPS Q/Q -54.55%
Profit margin -100.59%
Oper. margin -68.60%
Gross margin 25.97%
EBIT margin -74.69%
EBITDA margin -65.76%
Ret. on assets -46.42%
Ret. on equity -606.04%
ROIC -30.54%
ROCE -86.60%
Volatility 532.91%
Beta 0.00
RSI 31.69
Range $0.20 – $0.20
52 weeks $0.09 – $0.21
SMA 50 $0 +72.50%
SMA 200 $0 +95.00%
1 year target $27 +13,605.00%
Mean Recomm. 1.00
Shares outst. 8.663M
Shares float 0.000 0.00%
Short % of float 3.15%
Short ratio 3.79

Recent Athenex Inc news

Monday, 2 May 2022
 
yahoo
Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Present Phase 1 Clinical Data for KUR-501, an autologous GD2 CAR-NKT Cell Therapy for Relapsed/Refractory High Risk Neuroblastoma a - Yahoo Finance
Thursday, 13 January 2022
 
bizjournals
Inside the Athenex-ImmunityBio deal — and the California company's employment plans
Tuesday, 30 November 2021
 
yahoo
Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer - Yahoo Finance
Sunday, 7 November 2021
 
fool
Athenex, inc Q3 2021 Earnings Call Transcript
Friday, 7 May 2021
 
fool
Athenex, Inc. Q1 2021 Earnings Call Transcript
Wednesday, 5 May 2021
 
yahoo
Athenex Snaps Up Kuur Therapeutics For $185M; Street Sees 133.7% Upside
Monday, 3 May 2021
 
yahoo
MAY 3, 2021 ATNX INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
Sunday, 2 May 2021
 
yahoo
ATNX DEADLINE ALERT: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex Investors to Monday May 3rd Application Deadline in Securities Class Action, Advises Investors with Losses to Contact the Firm Immediately
Friday, 30 April 2021
 
yahoo
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX
yahoo
ATNX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Athenex, Inc.
yahoo
ATNX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of May 3, 2021 in the Class Action Filed on Behalf of Athenex, Inc. Limited Shareholders
yahoo
ATNX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Athenex, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 3, 2021
Thursday, 29 April 2021
 
yahoo
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Athenex, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 3, 2021 - ATNX
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex Investors to May 3rd Securities Class Action Deadline, Encourages Investors with Losses to Contact the Firm Immediately
yahoo
ATNX FINAL DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors With Losses to Secure Counsel Before Important Monday Deadline in Securities Class Action - ATNX
Wednesday, 28 April 2021
 
yahoo
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline - ATNX
yahoo
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Athenex, Inc. and Encourages Investors to Contact the Firm
yahoo
ATHENEX INVESTOR ALERT: Shareholder Lawsuit Filed
yahoo
Bronstein, Gewirtz & Grossman, LLC Reminds Athenex, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: May 3, 2021
yahoo
MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Tuesday, 27 April 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athenex Investors of May 3rd Application Deadline in Securities Class Action, Investors with Losses Should Contact the Firm Before Deadline
Monday, 26 April 2021
 
yahoo
Scott+Scott Attorneys at Law LLP Alerts Investors to Securities Class Action Against Athenex, Inc. and May 3 Deadline
yahoo
7-DAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Saturday, 24 April 2021
 
yahoo
Rosen, A Leading Law Firm, Encourages Athenex, Inc. Investors with Losses Over $100K to Secure Counsel Before Important May 3 Deadline in Securities Class Action - ATNX
Friday, 23 April 2021
 
yahoo
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors With Losses Over $100K to Secure Counsel Before Important May 3 Deadline in Securities Class Action - ATNX
yahoo
ATNX 10-DAY DEADLINE ALERT: HAGENS BERMAN Notifies Athenex Investors of May 3rd Application Deadline in Securities Class Action, Encourages Investors with Losses to Contact Its Attorneys
yahoo
MAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Thursday, 22 April 2021
 
yahoo
ATHENEX INVESTOR ALERT: Class Action Lawsuit Filed
Wednesday, 21 April 2021
 
yahoo
ATNX 12-DAY DEADLINE ALERT: HAGENS BERMAN Reminds Athenex Investors of May 3rd Application Deadline in Securities Class Action, Encourages Investors with Losses to Contact Its Attorneys
yahoo
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Velodyne Lidar, Renewable Energy Group, Athenex, and Ontrak and Encourages Investors to Contact the Firm - Yahoo Finance
Tuesday, 20 April 2021
 
yahoo
LAWSUIT FILED: Block & Leviton LLP Has Filed a Lawsuit Against Athenex, Inc. for Securities Fraud; Investors Who Lost Money Should Contact the Firm
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Athenex Investors to May 3rd Deadline in Securities Class Action, Encourages Investors with Losses to Contact Its Attorneys
Monday, 19 April 2021
 
yahoo
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Athenex, Inc., of Class Action Lawsuit and Upcoming Deadline - ATNX
Wednesday, 14 April 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex Investors with Losses to Contact Its Attorneys, Securities Class Action Filed and Important Deadline Established
Monday, 12 April 2021
 
yahoo
Rosen, A Trusted and Leading Law Firm, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline - ATNX
Thursday, 8 April 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex Investors with Losses to Contact Its Attorneys, Securities Class Action Filed
Tuesday, 6 April 2021
 
yahoo
UPCOMING DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Saturday, 3 April 2021
 
yahoo
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Athenex, Inc. Investors With Losses to Secure Counsel Before Important May 3 Deadline – ATNX
Thursday, 1 April 2021
 
yahoo
ATNX INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline - ATNX
Monday, 29 March 2021
 
yahoo
ROSEN, A LONGSTANDING LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important May 3 Deadline - ATNX
Thursday, 25 March 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athenex Investors of Securities Fraud Lawsuit and Important Deadlines, Encourages Investors with Losses to Contact Its Attorneys
yahoo
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. Investors
Wednesday, 24 March 2021
 
yahoo
SHAREHOLDER ALERT: Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders
Tuesday, 23 March 2021
 
yahoo
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors to Secure Counsel Before Important May 3 Deadline - ATNX
Monday, 22 March 2021
 
yahoo
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athenex, Inc.
Sunday, 21 March 2021
 
yahoo
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Athenex, Inc. - ATNX
Thursday, 18 March 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies Athenex Investors of Securities Class Action and Important Deadline, Encourages Investors with Losses to Contact Its Attorneys
yahoo
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Wednesday, 17 March 2021
 
yahoo
ATNX BREAKING NEWS: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Athenex, Inc. Investors to Secure Counsel Before Important Deadline - ATNX
Tuesday, 16 March 2021
 
yahoo
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Friday, 12 March 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Athenex Investors of Filing of Securities Fraud Lawsuit, Encourages Investors with Losses to Contact Its Attorneys
Wednesday, 10 March 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Announces Filing of Securities Fraud Class Action on Behalf of Athenex Shareholders, Encourages Investors with Losses to Contact Its Attorneys
Tuesday, 9 March 2021
 
yahoo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex Investors with Losses to Contact Its Attorneys, Securities Fraud Case Filed
Monday, 8 March 2021
 
apnews
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. Investors
Saturday, 6 March 2021
 
yahoo
ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Athenex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - ATNX
Friday, 5 March 2021
 
yahoo
SHAREHOLDER ALERT: Robbins LLP Announces That Athenex, Inc. is Being Sued for Misleading Shareholders
yahoo
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
yahoo
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Athenex, Inc. Investors
yahoo
Bronstein, Gewirtz & Grossman, LLC Notifies Athenex, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
yahoo
ATNX INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athenex, Inc.
8-K 2 Oct 2023 Bankruptcy or Receivership; Completion of Acquisition or Disposition of Assets; Material Modifications to R...
8-K 17 Aug 2023 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
8-K 18 Jul 2023 Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement; Bankruptcy or R...
8-K 22 May 2023 Bankruptcy or Receivership; Triggering Events That Accelerate or Increase a Direct Financial Obligation or ...
8-K 3 May 2023 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K 25 Apr 2023 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
8-K 31 Mar 2023 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Financial Statements and Exhibits
8-K 20 Mar 2023 Results of Operations and Financial Condition; Financial Statements and Exhibits
10-K 20 Mar 2023 Yearly report
8-K 14 Feb 2023 Material Modifications to Rights of Security Holders; Amendments to Articles of Incorporation or Bylaws; Ch...
8-K 22 Nov 2022 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compens...
Insider
Trans.
Transaction
Price per share Total value
Joe Annoni Chief Financial Officer Option 22 Feb 2023 $2.66 $1,663
Timothy De Vere Cook See Remarks Option 16 Sep 2022 $0.41 $919
Daniel Lang Pres Cell Therapy and VP Corp Dev Option 16 Sep 2022 $0.41 $5,108
Johnson Yiu Nam Lau CEO and Chairman of the Board Buy 19 Aug 2022 $0.45 $9,000
John Vierling Director Option 3 Aug 2022 $0.58 $4,355
Benson Kwan Hung Tsang Director Option 3 Aug 2022 $0.58 $5,806
Robert J. Spiegel Director Option 3 Aug 2022 $0.58 $5,080
Jordan Kanfer Director Option 3 Aug 2022 $0.58 $4,355
Manson Fok Director Option 3 Aug 2022 $0.58 $3,629
Stephanie A Davis Director Option 3 Aug 2022 $0.58 $5,080
Jinn Wu Director Buy 3 Aug 2022 $0.42 $4,200
Q3 2021
7 November 2021
Q3 2021 Earnings Call Transcript
Q2 2021
6 August 2021
Q2 2021 Earnings Call Transcript
Q1 2021
7 May 2021
Q1 2021 Earnings Call Transcript
Q4 2020
1 March 2021
Q4 2020 Earnings Call Transcript
Q3 2020
6 November 2020
Q3 2020 Earnings Call Transcript
Q2 2020
7 August 2020
Q2 2020 Earnings Call Transcript
Q1 2020
9 May 2020
Q1 2020 Earnings Call Transcript
Q4 2019
28 February 2020
Q4 2019 Earnings Call Transcript
Q3 2019
8 November 2019
Q3 2019 Earnings Call Transcript
Q2 2019
7 August 2019
CEO Johnson Lau on Q2 2019 Results - Earnings Call Transcript
Q2 2019
7 August 2019
Q2 2019 Earnings Call Transcript

2,727 people own Athenex Inc on Robinhood

Powered by Robintrack.

Overall analyst rating

Price target

Current $0.20
Average $27.41
Low $17 High $38

Athenex Inc executives

Insider Age Since Compensation
Johnson Lau (59) Chief Executive Officer and Chairman of the Board since 2011 59 2011 $4,483,840
Rudolf Kwan (67) Chief Medical Officer since 2014 67 2014 $1,473,850
Jeffrey Yordon (71) Chief Operating Officer, President, and Athenex Pharmaceutical Division since 2017 71 2017 $1,387,830
Randoll Sze (39) Chief Financial Officer since 2018 39 2018 $942,989
Simon Pedder (59) Chief Business and Strategy Officer - Proprietary Products since 2019 59 2019 $860,546
Jeffrey M. Yordon (72) COO and Pres of Athenex Pharmaceutical Division 72 $693,454
Dr. Rudolf Kwan M.D., M.B., B.S. (68) Chief Medical Officer 68 $483,205
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D. (61) Chairman and CEO 61 $480,747
Benson Tsang (55) Independent Director since 2018 55 2018 $184,036
Stephanie Davis (56) Independent Director since 2019 56 2019 $156,239
Kim Campbell (73) Lead Independent Director since 2015 73 2015 $151,960
Jinn Wu (71) Independent Director since 2007 71 2007 $149,960
Jordan Kanfer (50) Independent Director since 2019 50 2019 $117,740
John Vierling (74) Independent Director since 2019 74 2019 $114,740
Manson Fok (63) Director since 2015 63 2015 $105,807
Robert Spiegel (70) Director since 2020 70 2020
Daniel Lang 2019
Tim McCarthy 2017
William Zuo (58) President and China Division since 2015 58 2015
Dr. Wing-Kai Chan
John W. Matthei
Caileigh Dougherty
Michael Smolinski Ph.D.
Steven J. Adams (53) Interim Chief Accounting Officer 53
Daniel Lang M.D.
Jacqueline Li
Steven Rubis
Teresa Brophy Bair
Dr. Allen Barnett
Company Market cap P/E EV/EBITDA P/S P/B P/FCF Change
$69.11M 0.00 N/A 0.67 -10.62 N/A -26.65%
$203.64B 20.53 12.01 4.36 4.36 17.40 -0.75%

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

  • Health Care > Biotechnology
  • Athenex Inc, Conventus Building, Buffalo 14203, United States
  • 716 427 2950
  • Investor relations

Quarterly EPS estimates

Profit margin

Debt to assets

Cash flow

(in millions USD) 31 Dec 2022 30 Sep 2022 30 Jun 2022 31 Mar 2022
Current assets
Cash $35.62 $40.412 $35.964 $40.974
Short term investments $1.071 $1.034 $1.189 $10.235
Net receivables $27.865 $32.912 $33.824 $29.605
Inventory $42.654 $42.039 $37.851 $41.253
Total current assets $124.929 $126.706 $117.746 $131.588
Long term investments
Property, plant & equipment $6.043 $8.351 $9.079 $32.659
Goodwill & intangible assets $72.112 $72.168 $72.472 $71.567
Total noncurrent assets $79.126 $101.644 $104.141 $105.274
Total investments $1.071 $1.034 $1.189 $10.235
Total assets $204.055 $228.35 $221.887 $236.862
Current liabilities
Accounts payable $33.682 $25.071 $21.397 $16.605
Deferred revenue
Short long term debt $39.214 $16.953 $25.815 $27.221
Total current liabilities $114.879 $84.903 $90.171 $80.784
Long term debt $89.889 $105.781 $101.13 $106.514
Total noncurrent liabilities $113.357 $136.211 $137.189 $135.279
Total debt $129.103 $122.734 $126.945 $133.735
Total liabilities $228.236 $221.114 $227.36 $216.063
Stockholders' equity
Retained earnings -$1,016.839 -$982.658 -$962.989 -$930.832
Other stockholder equity $0.887 $2.987 $1.471 $0.075
Total stockholder equity -$6.506 $24.845 $11.935 $37.99
(in millions USD) 2022 2021 2020
Current assets
Cash $35.62 $51.702 $86.087
Short term investments $1.071 $10.207 $138.636
Net receivables $27.865 $26.637 $23.603
Inventory $42.654 $34.685 $28.846
Total current assets $124.929 $133.396 $291.961
Long term investments
Property, plant & equipment $6.043 $34.221 $42.309
Goodwill & intangible assets $72.112 $71.896 $49.109
Total noncurrent assets $79.126 $134.052 $92.368
Total investments $1.071 $10.207 $138.636
Total assets $204.055 $267.448 $384.329
Current liabilities
Accounts payable $33.682 $16.742 $18.673
Deferred revenue
Short long term debt $39.214 $49.79 $5.195
Total current liabilities $114.879 $96.047 $62.141
Long term debt $89.889 $107.95 $152.932
Total noncurrent liabilities $113.357 $136.949 $156.84
Total debt $129.103 $157.74 $158.127
Total liabilities $228.236 $232.996 $218.981
Stockholders' equity
Retained earnings -$1,016.839 -$913.412 -$713.644
Other stockholder equity $0.887 -$0.487 -$1.134
Total stockholder equity -$6.506 $51.131 $179.775

Income statement

(in millions USD) 31 Dec 2022 30 Sep 2022 30 Jun 2022 31 Mar 2022
Revenue
Total revenue $8.633 $33.53 $31.516 $29.724
Cost of revenue $2.461 $27.736 $23.092 $23.295
Gross profit $6.172 $5.794 $8.424 $6.429
Operating activities
Research & development $15.365 $9.214 $13.094 $13.99
Selling, general & administrative $4.463 $9.438 $17.172 $14.935
Total operating expenses $19.907 $18.652 $30.266 $28.925
Operating income -$13.735 -$12.858 -$21.842 -$22.496
Income from continuing operations
EBIT -$23.686 -$12.802 -$27.869 -$12.871
Income tax expense -$0.259 $0.596 -$0.019 $0.028
Interest expense $10.754 $6.271 $4.307 $4.521
Net income
Net income -$34.181 -$19.669 -$32.157 -$17.42
Income (for common shares) -$34.181 -$19.669 -$32.157 -$17.42
(in millions USD) 2022 2021 2020
Revenue
Total revenue $102.821 $120.181 $144.391
Cost of revenue $76.118 $82.406 $95.355
Gross profit $26.703 $37.775 $49.036
Operating activities
Research & development $51.758 $80.197 $75.904
Selling, general & administrative $44.88 $72.553 $96.855
Total operating expenses $96.717 $222.169 $172.759
Operating income -$70.014 -$184.394 -$123.723
Income from continuing operations
EBIT -$77.237 -$189.63 -$130.872
Income tax expense $0.347 -$10.604 $4.088
Interest expense $25.843 $20.742 $11.219
Net income
Net income -$103.427 -$199.768 -$146.179
Income (for common shares) -$103.427 -$199.768 -$146.179
(in millions USD) 31 Dec 2022 30 Sep 2022 30 Jun 2022 31 Mar 2022
Net income -$34.181 -$19.669 -$32.157 -$17.42
Operating activities
Depreciation $0.106 $0.746 $0.598 $0.872
Business acquisitions & disposals
Stock-based compensation $1.44 $1.409 $1.603 $1.874
Total cash flows from operations -$14.394 -$16.274 -$20.457 -$23.889
Investing activities
Capital expenditures $0.056 -$0.113 -$0.193 -$0.167
Investments $0.05 $0.058 $9.488
Total cash flows from investing $12.505 -$0.81 $8.324 $37.883
Financing activities
Dividends paid
Sale and purchase of stock $3.595 $20.647 $2.968 $1.695
Net borrowings -$3.372 -$8.873 $3.873 -$27.064
Total cash flows from financing $0.103 $20.781 $6.056 -$25.376
Effect of exchange rate -$3.006 $0.751 $1.067 $0.654
Change in cash and equivalents -$1.786 $3.697 -$6.077 -$11.382
(in millions USD) 2022 2021 2020
Net income -$103.427 -$199.768 -$146.179
Operating activities
Depreciation $2.322 $4.682 $4.492
Business acquisitions & disposals $1.526
Stock-based compensation $6.326 $9.207 $10.85
Total cash flows from operations -$75.014 -$142.379 -$131.243
Investing activities
Capital expenditures -$0.417 -$8.398 -$13.256
Investments $9.596 $128.936 -$105.502
Total cash flows from investing $57.902 $104.984 -$118.972
Financing activities
Dividends paid
Sale and purchase of stock $28.905 $2.843 $135.742
Net borrowings -$35.436 -$0.203 $81.356
Total cash flows from financing $1.564 $2.462 $209.427
Effect of exchange rate -$0.534 $0.548 -$0.799
Change in cash and equivalents -$15.548 -$34.933 -$40.788

Recent institutional transactions

Quarter Shareholder Change
Shares owned
Shares
Value (in thousands USD)
2023 Q2 Acadian Asset Management
Sold out
48,556 $6
2023 Q2 B. Riley Wealth Advisors
Sold out
22,497 $2,925
2023 Q1 National Bank Of Canada fi/
Sold out
175 $228
2022 Q4 Renaissance Technologies
Sold out
1,205,528 $178
2022 Q3 Citadel Advisors
-86.81%
77,162 $20
2022 Q3 Millennium Management
-8.92%
4,169,818 $1,123
2022 Q2 Occudo Quantitative Strategies L.P.
Sold out
151,987 $62
2022 Q2 Aqr Capital Management
Sold out
109,447 $45
2022 Q2 D. E. Shaw & Co
Sold out
29,409 $12
2022 Q2 Brinker Capital Investments
Sold out
27,688 $11

Institutional shareholders

Shareholder Stake
Shares owned
Shares
Value (in thousands USD)
Millennium Management 48.13% 4,169,818
Alyeska Investment L.P. 23.09% 2,000,000
Renaissance Technologies 13.92% 1,205,528
Greenwoods Asset Management Ltd 5.75% 498,510
Occudo Quantitative Strategies L.P. 1.75% 151,987
Tiaa Cref Investment Management 1.51% 130,387
Aqr Capital Management 1.26% 109,447
Parametric Portfolio Associates 1.21% 104,740
Spearhead Capital Advisors 1.12% 97,169
Citadel Advisors 0.89% 77,162